To make disease-modifying first-in-class treatments available to patients suffering from conditions such as cancer, cognitive decline and fibrosis.
Medibiofarma discovers and develops new chemical entities (NCEs) with clinical proof-of-concept data in human patients
Medibiofarma focuses internal resources in the followings areas:
The remaining activities for the full characterization and nomination of a development candidate, such as in vivo pharmacology, toxicology and IND-enabling studies are carried out through partnerships with several companies (CROs), Research Centers and Universities.
Navarra – December 2022 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases announced the first...
Medibiofarma has just closed a financing round of 1.2 million euros, supported by the founder’s and other VC partners with proven experience in the field of health and technology, such as Sodena...
